Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel
TSE:HBP

Helix BioPharma 10/24/2024 Earnings Report

Helix BioPharma logo
C$2.04 0.00 (0.00%)
As of 05/4/2026 03:56 PM Eastern
ProfileEarnings History

Helix BioPharma EPS Results

Actual EPS
-C$0.11
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Helix BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Helix BioPharma Announcement Details

Quarter
Date
10/24/2024
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Helix BioPharma Earnings Headlines

Helix BioPharma Showcases CEACAM6-Targeted ADC Advances at World ADC London
February 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/helix-biopharma-showcases-ceacam6-targeted-adc-advances-at-world-adc-london?utm_source=marketbeat.com&utm_medium=referral
Helix BioPharma Extends LEUMUNA Option with metaShape in Metabolic Disease Push
February 5, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/helix-biopharma-extends-leumuna-option-with-metashape-in-metabolic-disease-push?utm_source=marketbeat.com&utm_medium=referral
Elon Musk’s $1 Quadrillion AI IPO
$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.tc pixel
May 5 at 1:00 AM  |  Brownstone Research (Ad)
Helix BioPharma Shareholders Back Board, Auditor and Share Consolidation Plan
January 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/helix-biopharma-shareholders-back-board-auditor-and-share-consolidation-plan?utm_source=marketbeat.com&utm_medium=referral
Helix BioPharma Reports Fiscal 2025 Results and Strategic Developments
October 29, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/helix-biopharma-reports-fiscal-2025-results-and-strategic-developments?utm_source=marketbeat.com&utm_medium=referral
Helix BioPharma Addresses Unusual Market Activity Amidst Ongoing Cancer Treatment Developments
October 6, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/helix-biopharma-addresses-unusual-market-activity-amidst-ongoing-cancer-treatment-developments?utm_source=marketbeat.com&utm_medium=referral
See More Helix BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Helix BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Helix BioPharma and other key companies, straight to your email.

About Helix BioPharma

Helix BioPharma (TSE:HBP) is an oncology company that innovates from strength to bring near-term solutions for today's hardest-to-treat cancers. The Company's pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today's front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix's next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery. The Company also advances two pre-IND candidates: (i) LEUMUNA¿, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and (ii) GEMCEDA¿, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.

View Helix BioPharma Profile
Earnings Tools